For decades, the clinical world has relied heavily on albumin-adjusted—or “corrected”—calcium measurements in blood tests to estimate the biologically active calcium fraction in patients. This long-established laboratory practice involves mathematically adjusting total serum calcium concentrations according to albumin levels, under the assumption that it more accurately reflects ionized calcium, which is the physiologically relevant form of calcium in the body. However, a compelling new position statement published in the respected journal Clinical Chemistry and Laboratory Medicine is challenging this dogma. An international coalition of leading experts in laboratory medicine, chronic kidney disease (CKD), and osteoporosis is urging healthcare providers and laboratories worldwide to cease routine reporting of albumin-adjusted calcium due to emerging evidence indicating its limited validity and potential to cause diagnostic confusion and patient harm.
The position statement emerges from a collaboration of prominent organizations including the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM), the International Osteoporosis Foundation (IOF), and the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC). They collectively underscore that the conventional formula-based correction methods are increasingly seen as inadequate, especially in complex clinical scenarios. Specifically, it is becoming evident that these correction algorithms tend to falter in patients suffering from chronic illnesses, advanced renal failure, inflammatory states, acid-base imbalances, or hypoalbuminemia, which are precisely the patient groups most vulnerable to misinterpretation.
At its core, the invocation of albumin correction relies on the premise that serum calcium is bound predominantly to albumin and that the unbound, ionized fraction drives physiological processes such as neuromuscular function and bone metabolism. Hence, adjusting total calcium for albumin concentration has been thought to normalize results for fluctuations in protein binding. Nevertheless, mounting research has shown that this simplistic correction often does not hold up when directly compared with ionized calcium measurements. Ionized calcium is the gold standard but is technically more demanding to measure accurately, requiring specialized handling to avoid pH and temperature artifacts.
Professor Etienne Cavalier of the University of Liège, a leading voice in this initiative, emphasizes that while albumin-corrected calcium is entrenched in clinical workflows globally, its validation against ionized calcium is surprisingly scarce. The working group points out that reliance on corrected calcium can paradoxically lead to diagnostic inaccuracies, masking genuine hypocalcemia in some patients and falsely suggesting hypercalcemia in others. These lapses have profound therapeutic implications, particularly in nephrology where calcium balance management is critical.
Patients with chronic kidney disease or those on dialysis are frequently dependent on precise calcium measurement for tailoring treatments involving vitamin D analogues, calcimimetics, phosphate binders, and adjustments to dialysis prescriptions. Mistakes here can exacerbate vascular calcification or bone disease, conditions with significant morbidity and mortality. The statement warns that using corrected calcium in these cohorts might mislead clinicians, potentially triggering inappropriate treatments or delaying necessary intervention.
Analytical variability further complicates the issue. Different laboratories employ diverse methods for measuring albumin, and these methodological disparities undermine the consistency of albumin-corrected values. This lack of standardization introduces an additional source of uncertainty, limiting the reproducibility and clinical utility of corrected calcium assays across different healthcare settings.
In light of this evidence, the expert consensus strongly recommends shifting away from the routine reporting of albumin-corrected calcium. Instead, the default laboratory report should provide unadjusted total calcium. Clinicians should request ionized calcium testing in scenarios where calcium status critically impacts patient management or the interpretation of calcium levels is challenging due to confounding factors such as severe hypoalbuminemia or acid-base disturbances.
Moreover, the working group advocates for ionized calcium to become the preferred primary test in high-risk groups, provided that the rigor of sampling and analytical protocols are maintained to ensure accuracy. This approach aligns with physiological principles and reflects a more evidence-based understanding of calcium homeostasis in health and disease.
The statement also highlights a striking global heterogeneity in laboratory practices regarding calcium measurement. Some labs have entirely abandoned corrected calcium reporting, whereas others continue its automatic generation whenever calcium and albumin are measured concurrently. This divergence underscores a pressing need for harmonization to promote patient safety, diagnostic reliability, and streamlined clinical workflows.
Abandoning routine albumin-adjusted calcium not only simplifies laboratory reports but promises to reduce diagnostic ambiguity. It helps align laboratory medicine with contemporary clinical evidence and physiological insights, eradicating a potentially obsolete practice rooted more in tradition than in robust science. Ultimately, this shift could contribute to improved patient outcomes by enabling clinicians to make better-informed decisions grounded in more accurate assessments of calcium metabolism.
The emerging consensus represents a significant paradigm shift in biomarker diagnostics and clinical chemistry. It challenges established norms and invites laboratories and clinicians to critically reevaluate protocols long considered standard. As the evidence base continues to expand, incorporating direct ionized calcium assays tailored to specific patient populations may set a new benchmark in metabolic monitoring.
In summary, this landmark position paper calls on the global medical community to reexamine and ultimately discontinue the default use of albumin-adjusted calcium measurements. It urges adoption of unadjusted total calcium as a baseline test, with ionized calcium reserved for critical or ambiguous cases. The authors argue this strategy will better reflect biological reality, enhance diagnostic accuracy, and prevent clinical mismanagement, particularly in vulnerable patients with kidney disease or complex metabolic disorders.
This development exemplifies the evolving interface between laboratory science and clinical practice, where innovation and evidence-based refinement continuously reshape diagnostic standards. Moving forward, strengthening education and updating guidelines will be essential to facilitate this transition and ensure optimal care for patients worldwide.
Subject of Research: Human tissue samples
Article Title: Albumin-adjusted (“corrected”) calcium should no longer be reported: a position statement from the Joint IOF Working Group and IFCC Committee on Bone Metabolism and EFLM Committee on CKD
News Publication Date: 20-Apr-2026
Web References: https://www.degruyterbrill.com/document/doi/10.1515/cclm-2026-0545/html, https://www.osteoporosis.foundation/, https://www.eflm.eu/site/, http://dx.doi.org/10.1515/cclm-2026-0545
References: Cavalier, Etienne, et al. “Albumin-adjusted (‘corrected’) calcium should no longer be reported: a position statement from the Joint IOF Working Group and IFCC Committee on Bone Metabolism and EFLM Committee on CKD.” Clinical Chemistry and Laboratory Medicine (CCLM), 2026. DOI: 10.1515/cclm-2026-0545
Keywords: calcium measurement, albumin correction, ionized calcium, chronic kidney disease, laboratory medicine, diagnostic accuracy, biochemical biomarkers, metabolic monitoring, nephrology, osteoporosis, clinical chemistry, laboratory standardization
